Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (471-480 of 610) with videos related to

Pageof 61
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemiaFrancis J Giles, Guillermo Garcia-Manero, Jorge E Cortes, et al.
Leukemia & Lymphoma|November 9, 2001
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndromeB S Dabaja, S M O'Brien, H M Kantarjian, et al.
British Journal of Haematology|February 13, 2003
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemiaWilliam G Wierda, Marcella M Johnson, Kim-Anh Do, et al.
Cancer|June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinosideGuillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.
Oncotarget|April 15, 2017
The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor traffickingAkio Soeda, Justin Lathia, Brian J Williams, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2003
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemiaApostolia M Tsimberidou, Elihu Estey, Jorge E Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignanciesMonica Mita, Kevin R Kelly, Alain Mita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabineH M Kantarjian, S O'Brien, T L Smith, et al.
Blood|January 13, 2006
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or olderStefan Faderl, Srdan Verstovsek, Jorge Cortes, et al.
Cancer|April 4, 2006
Thalidomide therapy for myelofibrosis with myeloid metaplasiaDeborah A Thomas, Francis J Giles, Maher Albitar, et al.
Pageof 61

Showing results (471-480 of 610) with videos related to

Sort By:
Pageof 61
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemiaFrancis J Giles, Guillermo Garcia-Manero, Jorge E Cortes, et al.
Leukemia & Lymphoma|November 9, 2001
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndromeB S Dabaja, S M O'Brien, H M Kantarjian, et al.
British Journal of Haematology|February 13, 2003
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemiaWilliam G Wierda, Marcella M Johnson, Kim-Anh Do, et al.
Cancer|June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinosideGuillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.
Oncotarget|April 15, 2017
The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor traffickingAkio Soeda, Justin Lathia, Brian J Williams, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2003
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemiaApostolia M Tsimberidou, Elihu Estey, Jorge E Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignanciesMonica Mita, Kevin R Kelly, Alain Mita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabineH M Kantarjian, S O'Brien, T L Smith, et al.
Blood|January 13, 2006
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or olderStefan Faderl, Srdan Verstovsek, Jorge Cortes, et al.
Cancer|April 4, 2006
Thalidomide therapy for myelofibrosis with myeloid metaplasiaDeborah A Thomas, Francis J Giles, Maher Albitar, et al.
Pageof 61